Gain Therapeutics (GANX) Price & Analysis

Compare

341 Followers

GANX Stock Chart & Stats

$1.81

-$0.01(-0.44%)

At close: Jan 08 4:00 PM EST

$1.81

-$0.01(-0.44%)

Day’s Range― - ―

52-Week Range$1.41 - $2.90

Previous CloseN/A

Volume74.47K

Average Volume (3M)849.30K

Market Cap

$65.07M

Enterprise Value$48.60M

Total Cash (Recent Filing)$6.69M

Total Debt (Recent Filing)$229.17K

Price to Earnings (P/E)―

Beta1.43

Next Earnings

Nov 07, 2025

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding35,948,605

10 Day Avg. Volume1,205,771

30 Day Avg. Volume849,304

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.75

Enterprise Value/Revenue590.95

Enterprise Value/Gross Profit-764.05

Enterprise Value/Ebitda-2.82

Forecast

1Y Price Target

$6.80

Price Target Upside275.69% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Drug EfficacyGT-02287 has a disease-slowing effect and is consistent with the preclinical models and the proposed mechanism of action.

Regulatory ApprovalAustralian health authorities have approved an extension to the trial; patients can be treated for up to 12 months.

Safety ProfileThe independent data monitoring committee reported no safety concerns and recommended continuing the study, which boosts confidence in the drug's safety profile.

Bears Say

Trial DurationThe extension of the Phase 1b study is expected to better inform Phase 2 protocol design and planning.

Gain Therapeutics News

Gain Therapeutics price target lowered to $5 from $9 at BTIG

BTIG lowered the firm’s price target on Gain Therapeutics (GANX) to $5 from $9 and keeps a Buy...

2d ago

GANX

Gain Therapeutics price target raised to $7 from $5 at Maxim

Maxim raised the firm’s price target on Gain Therapeutics (GANX) to $7 from $5 and keeps a Buy...

11d ago

GANX

Unusually active option classes on open October 6th

Unusual total active option classes on open include: Gain Therapeutics (GANX), Arteris (AIP), Northern Dynasty (NAK), Cedar Fair...

12d ago

AIP

FLY

Gain Therapeutics presents initial data from Phase 1b study of GT-02287

Gain Therapeutics (GANX) presented a poster at the International Congress of Parkinson’s Disease and Movement Disorders summarizing early...

12d ago

GANX

Gain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’s

Gain Therapeutics (GANX) announced the start of the Phase 1b extension study allowing participants to continue treatment for...

30d ago

GANX

Buy Rating for Gain Therapeutics: Promising Potential of GT-02287 in Parkinson’s Treatment

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Gain Therapeutics, retaining the price target of...

16h ago

GANX

Eric Richman Resigns from Gain Therapeutics Board

Gain Therapeutics ( ($GANX) ) has issued an announcement. On October 6, 2025, Eric Richman resigned from Gain...

8d ago

GANX

Positive Buy Rating for Gain Therapeutics Driven by Promising Clinical Trial Developments and Strong Financial Outlook

Analyst Thomas Shrader of BTIG maintained a Buy rating on Gain Therapeutics, retaining the price target of $9.00....

1M ago

GANX

Promising Developments and Regulatory Milestones Bolster Buy Rating for Gain Therapeutics

Maxim Group analyst Jason McCarthy maintained a Buy rating on Gain Therapeutics yesterday and set a price target...

1M ago

GANX

Gain Therapeutics receives Australian approval of Phase 1b dosing extension

Gain Therapeutics (GANX) announced the Company has received approval from the Bellberry Human Research Ethics Committee and Alfred...

1M ago

GANX

Buy Rating Reaffirmed for Gain Therapeutics Amid Promising Clinical Developments and Strong Financial Positioning

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Gain Therapeutics, with...

2M ago

GANX

Gain Therapeutics Reports Q2 2025 Financial Results

Gain Therapeutics, Inc. ( ($GANX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

GANX

Buy Recommendation for Gain Therapeutics Driven by Promising Parkinson’s Drug Development and Strong Financial Position

Gain Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

2M ago

GANX

Gain Therapeutics price target lowered to $6 from $7 at Roth Capital

Roth Capital lowered the firm’s price target on Gain Therapeutics (GANX) to $6 from $7 and keeps a...

2M ago

GANX

GANX FAQ

What was Gain Therapeutics’s price range in the past 12 months?

Gain Therapeutics lowest stock price was $1.41 and its highest was $2.90 in the past 12 months.

What is Gain Therapeutics’s market cap?

Gain Therapeutics’s market cap is $65.07M.

When is Gain Therapeutics’s upcoming earnings report date?

Gain Therapeutics’s upcoming earnings report date is Nov 07, 2025 which is in 20 days.

How were Gain Therapeutics’s earnings last quarter?

Gain Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.023.

Is Gain Therapeutics overvalued?

According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gain Therapeutics pay dividends?

Gain Therapeutics does not currently pay dividends.

What is Gain Therapeutics’s EPS estimate?

Gain Therapeutics’s EPS estimate is -0.16.

How many shares outstanding does Gain Therapeutics have?

Gain Therapeutics has 35,948,605 shares outstanding.

What happened to Gain Therapeutics’s price movement after its last earnings report?

Gain Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went up 4.795%.

Which hedge fund is a major shareholder of Gain Therapeutics?

Currently, no hedge funds are holding shares in GANX

Gain Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-240.21%

Trailing 12-Months

Asset Growth

-48.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Gain Therapeutics

Gain Therapeutics, Inc. (GANX) is a biotechnology company operating in the healthcare sector, focusing on discovering and developing novel therapies to treat rare genetic disorders and neurological diseases. The company utilizes its proprietary SEE-Tx platform to identify and optimize allosteric binding sites on proteins, which can be targeted to restore normal function in misfolded proteins, a common cause of many serious diseases.

Gain Therapeutics (GANX) Earnings & Revenues

Historic Earnings Reports

GANX Stock 12 Month Forecast

Average Price Target

$6.80

▲(275.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.82,2.2953846153846156,2.770769230769231,3.246153846153846,3.7215384615384615,4.196923076923077,4.672307692307692,5.147692307692307,5.623076923076923,6.098461538461539,6.573846153846154,7.049230769230769,7.524615384615385,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.82,2.203076923076923,2.586153846153846,2.9692307692307693,3.352307692307692,3.735384615384615,4.118461538461538,4.501538461538462,4.884615384615384,5.2676923076923075,5.650769230769231,6.033846153846154,6.4169230769230765,{"y":6.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.82,2.0646153846153847,2.309230769230769,2.5538461538461537,2.7984615384615386,3.043076923076923,3.287692307692308,3.5323076923076924,3.776923076923077,4.021538461538461,4.266153846153846,4.51076923076923,4.7553846153846155,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.09,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >